Cipla Shares Jump 4% as Citi Predicts Major Near-Term Catalysts

Cipla shares surged as much as 4% to hit a high of Rs 1,409 on the BSE following a bullish update from global brokerage Citi. The Wall Street firm has placed the pharmaceutical giant on a "90-day Positive Catalyst Watch," maintaining a 'Buy' rating with a target price of Rs 1,700.

US Market Triggers and Regulatory Milestones

Citi’s optimism is largely rooted in several upcoming developments in the United States, which is expected to see a significant revenue rebound. Key drivers include the anticipated approval of gFlovent from Cipla’s Goa facility, a move that would substantially bolster its US growth trajectory. Additionally, the expected launch of gVentolin is viewed as a major milestone.

The brokerage also highlighted Cipla’s strong competitive position in the US, noting that its Nintedanib product has already captured nearly 50% of the market share. Beyond product launches, regulatory clearance remains a critical factor; a pending re-inspection of the Indore plant by the USFDA could act as a massive catalyst if the outcome is favorable.

Domestic Resilience and Valuation Advantages

While the US market provides growth triggers, Cipla’s domestic operations remain a bedrock of stability. The India business, which contributes nearly two-thirds of the company's EBITDA, is performing well due to a recovery in its respiratory portfolio.

From a valuation perspective, Citi argues that Cipla offers a more attractive entry point compared to its domestic peers. Specifically, Cipla’s India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma’s 8.5 times. The brokerage suggests that earnings have likely bottomed out following the impact of gRevlimid, presenting a favorable risk-reward profile for investors.

Analyzing Recent Financial Performance

The current optimism comes despite a challenging recent financial period for the pharma major. In the fourth quarter, Cipla reported a significant 55% year-on-year decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same quarter last year. Revenue from operations also saw a marginal dip of 3% to Rs 6,541 crore.

For the full financial year ending March 31, 2026, Cipla recorded a 2% YoY rise in revenue to Rs 28,163 crore, though net profit declined by 26% to Rs 3,879 crore. Despite these headwinds, the easing of geopolitical tensions is expected to help stabilize raw material costs and improve margins moving forward.

Key Takeaways

  • Bullish Target: Citi has set a target price of Rs 1,700 for Cipla, implying a potential upside of over 25% from recent levels.
  • US Growth Drivers: Key catalysts include the potential USFDA approval of gFlovent from the Goa plant and the upcoming launch of gVentolin.
  • Attractive Valuation: Cipla's domestic business offers a more reasonable valuation (7.8x FY26 sales) compared to industry peers like Mankind.